Schubert & Co Purchases Shares of 2,421 Danaher Co. (NYSE:DHR)

Schubert & Co acquired a new stake in Danaher Co. (NYSE:DHR) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,421 shares of the conglomerate’s stock, valued at approximately $673,000. Danaher accounts for approximately 0.5% of Schubert & Co’s portfolio, making the stock its 20th biggest holding.

Several other hedge funds and other institutional investors have also recently modified their holdings of DHR. Slow Capital Inc. purchased a new stake in Danaher in the third quarter worth $4,048,000. First Citizens Bank & Trust Co. lifted its position in shares of Danaher by 0.5% in the 3rd quarter. First Citizens Bank & Trust Co. now owns 39,861 shares of the conglomerate’s stock worth $11,082,000 after purchasing an additional 207 shares during the period. Blue Trust Inc. boosted its stake in shares of Danaher by 9.1% during the 3rd quarter. Blue Trust Inc. now owns 9,458 shares of the conglomerate’s stock valued at $2,630,000 after purchasing an additional 786 shares in the last quarter. Dixon Mitchell Investment Counsel Inc. increased its position in shares of Danaher by 5.4% during the third quarter. Dixon Mitchell Investment Counsel Inc. now owns 131,440 shares of the conglomerate’s stock valued at $36,578,000 after buying an additional 6,688 shares during the period. Finally, Meridian Financial Partners LLC lifted its holdings in Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate’s stock worth $266,000 after buying an additional 40 shares during the period. 79.05% of the stock is owned by institutional investors.

Insider Activity at Danaher

In other news, CEO Rainer Blair sold 9,007 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Rainer Blair sold 9,007 shares of Danaher stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total transaction of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at approximately $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 over the last 90 days. 11.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on DHR. Leerink Partners increased their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Wells Fargo & Company began coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price objective for the company. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Stephens initiated coverage on shares of Danaher in a research note on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price target for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $300.00 price objective on shares of Danaher in a research note on Friday, September 6th. Seven analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Stock Performance

NYSE:DHR traded up $2.40 during mid-day trading on Friday, reaching $274.38. The company’s stock had a trading volume of 1,949,849 shares, compared to its average volume of 2,717,951. The firm’s fifty day moving average price is $270.72 and its two-hundred day moving average price is $259.92. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. The stock has a market cap of $203.23 billion, a P/E ratio of 46.50, a PEG ratio of 4.49 and a beta of 0.83. Danaher Co. has a 12-month low of $182.09 and a 12-month high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.05 earnings per share. On average, equities analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.